U.S. markets closed

MiMedx Group, Inc. (MDXG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.1400+0.1400 (+3.50%)
At close: 04:00PM EDT
4.1400 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close4.0000
Bid3.2000 x 1800
Ask4.3500 x 800
Day's Range3.9900 - 4.2000
52 Week Range3.0400 - 15.9900
Avg. Volume499,608
Market Cap470.341M
Beta (5Y Monthly)1.79
PE Ratio (TTM)N/A
EPS (TTM)-0.1710
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MDXG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MiMedx Group, Inc
    Analyst Report: Integra Lifesciences Hldgs CorBased in Plainsboro, New Jersey, Integra is an integrated medical device company that develops and markets devices for use in neurosurgery and wound repair. The company's products are used in cranial and spinal procedures, peripheral nerve repair, the repair of skin and deeper tissue from burns and vehicular accidents, and the repair and reconstruction of soft tissue. It operates in two segments: Codman Specialty Surgical, and Tissue Technologies. The company also markets products through private-label relationships with other medical device companies.
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • GlobeNewswire

    MIMEDX to Present at the Canaccord Genuity 42nd Annual Growth Conference

    MARIETTA, Ga., Aug. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will present at the Canaccord Genuity 42nd Annual Growth Conference in Boston on Wednesday, August 10, 2022 at 3:00 p.m. Eastern Time. Institutional investors interested in a meeting with senior management may contact their Canaccord Genuity representative. Investors and other interested parties may

  • Zacks Small Cap Research

    MDXG: 2Q:22 Financial and Operational Results

    By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT After market close on August 2, 2022, MiMedx Group, Inc. (NASDAQ:MDXG) filed Form 10-Q with the SEC and issued a press release summarizing its financial and operational results for the quarter ended June 30, 2022. A conference call and webcast was held the following day to communicate additional detail to analysts and

  • GlobeNewswire

    MIMEDX Announces Second Quarter 2022 Operating and Financial Results

    Second Quarter Net Sales of $66.9 Million Reflects Double-Digit Revenue Increase for the Fourth Consecutive Quarter in the Company's Continuing Portfolio of Products Achieves Strong Year-Over-Year Revenue Growth in Key Focus Area of Surgical Recovery Company Reaffirms 2022 Revenue Growth Outlook of 11% to 14% in Continuing Portfolio of Products Management to Host Conference Call on Wednesday, August 3, 2022, at 8:30 AM ET MARIETTA, Ga., Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasda